Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia

NCT04351152 is registered in ClinicalTrials.gov with Humanigen, Inc. as lead sponsor.

NCT NCT04351152
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04351152 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 3 Randomized, Placebo-Controlled Study of Lenzilumab in Hospitalized Patients With Severe and Critical COVID-19 Pneumonia
Lead sponsor
Humanigen, Inc.
Phase
Phase 3
Overall status
Unknown status
Start date
May 5, 2020
Completion date
March 31, 2021
Enrollment
520 (actual)
Sites
29

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus disease 2019 (covid-19) pneumonia